跳转至内容
Merck
CN

SML2926

Sigma-Aldrich

FT895

≥98% (HPLC)

别名:

2,3-Dihydro-N-hydroxy-1,1-dimethyl-2-[5-(trifluoromethyl)-2-pyrazinyl]-1H-isoindole-4-carboxamide, FT 895, FT-895, HDTK 070, HDTK-070, HDTK070, N-Hydroxy-1,1-dimethyl-2-(5-(trifluoromethyl)pyrazin-2-yl)isoindoline-4-carboxamide

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C16H15F3N4O2
化学文摘社编号:
2225728-57-2
分子量:
352.31
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

FC(F)(F)c1ncc(nc1)N2C(c3c(c(ccc3)C(=O)NO)C2)(C)C

InChI key

XCLPBILTRRWOIL-UHFFFAOYSA-N

相关类别

生化/生理作用

FT895 is a potent and highly selective HDAC11 inhibitor (IC50 = 3 nM/HDAC11, 5.6 μM/HDAC8, >10 μM/HDAC1-7, HDAC9 & HDAC10) with a deacetylase active site Zn2+-targeting hydroxamate. FT895 exhibits antiproliferation potency against myeloproliferative neoplasm (MPN) cultures (IC50 = 3.00 μM/JAK2(V617F) Ba/F3, 4.94 μM/HEL92.1.7, 6.49 μM/MPL(W515L) Ba/F3) and reduces stem-like properties of CSCs (42/62/85/100% inhibtion of H1650 Sphere formation at 0.5/1/2/5 μM).
Potent and highly selective HDAC11 inhibitor that reduces myeloproliferative neoplasm (MPN) proliferation and CSCs stem-like properties.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000190129
0000190130
0000190130
0000190129
0000119115

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Se In Son et al.
ACS chemical biology, 14(7), 1393-1397 (2019-07-03)
Mammalian histone deacetylases (HDACs) are a class of enzymes that play important roles in biological pathways. Existing HDAC inhibitors target multiple HDACs without much selectivity. Inhibitors that target one particular HDAC will be useful for investigating the biological functions of
Matthew W Martin et al.
Bioorganic & medicinal chemistry letters, 28(12), 2143-2147 (2018-05-20)
N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool
Namrata Bora-Singhal et al.
Scientific reports, 10(1), 4722-4722 (2020-03-15)
Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to development of resistance to chemotherapy agents and the EGFR inhibitors, which results in recurrence of highly aggressive lung tumors. Even with recent success in immunotherapy using

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持